Pfizer completes Icagen purchase

Published: 3-Nov-2011
Finance Pharmaceutical

US firm will be integrated into Pfizer’s research unit Neusentis


Pfizer has bought Icagen of Durham, NC, US by merging its subsidiary, Eclipse Acquisition, into Icagen. Biopharmaceutical firm Icagen is now a wholly owned subsidiary of Pfizer.

Icagen has joined Pfizer’s Worldwide Research and Development organisation, and will be integrated into Neusentis, Pfizer’s Research Unit, which includes pain, sensory disorders and regenerative medicine.

Icagen focuses on the discovery and development of small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads.

Ruth McKernan, senior vice president of Pfizer and chief scientific officer of Neusentis, commented: ‘We have worked closely with Icagen for several years and have the utmost respect for their expertise. Their understanding of ion channel mechanisms will enhance our ability to develop novel drugs for the treatment of pain and related disorders.’

  • Companies:
  • Pfizer
See more

You may also like

Pharmaceutical

Enanta Pharma files patent infringement suit against Pfizer in the Unified Patent Court of the EU

Read more
The company is seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the 265 Patent) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets)

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Almac expands bioavailability capabilities to address a critical need in drug development Almac Group has completed a multimillion-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK
  3. ProMach Pharma presents new equipment at Pack Expo Las Vegas Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
  4. Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
  5. Fidia Farmaceutici enters the UK market with the acquisition of Altacor Marking another significant milestone in its ongoing international expansion, the company enters the rapidly growing UK ophthalmology market, a key therapeutic area for the group

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Pharmaceutical

Enanta Pharma files patent infringement suit against Pfizer in the Unified Patent Court of the EU

The company is seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the 265 Patent) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets)
Manufacturing

Pfizer licenses 3SBio's oncology bispecific antibody, SSGJ-707 for up to $4.8bn

The bispecific antibody has demonstrated initial efficacy in patients with non-small cell lung metastatic colorectal cancer, as well as gynaecological tumours
Research & Development

Pfizer discontinues development of GLP-1 receptor agonist, danuglipron

The oral GLP-1 receptor agonist was discontinued due to reports of potential drug-induced liver toxicity in one patient during phase III trials
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Regulatory

Pfizer's haemophilia A/B therapeutic Hympavzi gains FDA approval

The pharma giant's once-weekly injectable can be administered subcutaneously and is able to significantly reduce annualised bleeding
Regulatory

Tivdak receives US FDA approval for treating recurrent cervical cancer

The full approval of tisotumab vedotin will offer a treatment for patients with metastatic or recurrent cervical cancer exhibiting disease progression on or after chemotherapy
Drug Delivery

Pfizer enters into merger with Seagen

The companies expect to complete the transaction in late 2023 or early 2024, subject to fulfilment of customary closing conditions
Subscribe now